NCT03926260 (ELUCID) is a NA clinical trial of ctDNA analysis in Metastatic Non-small Cell Lung Cancer, sponsored by Centre Hospitalier Departemental Vendee.

Who is sponsoring NCT03926260?

NCT03926260 is sponsored by Centre Hospitalier Departemental Vendee.

What drugs are being tested in NCT03926260?

Interventions in NCT03926260: ctDNA analysis.

What condition does NCT03926260 study?

NCT03926260 studies Metastatic Non-small Cell Lung Cancer.

Is NCT03926260 still recruiting?

NCT03926260 is currently completed. Last updated 4 December 2025.

Last reviewed 2025-12-04 · How we verify

NCT03926260: ELUCID

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Early Assessment of Response to Treatment of Metastatic LUng Tumors Based on CIrculating Tumor DNA

Completed NA Last updated 4 December 2025

What this trial tests

NA trial testing ctDNA analysis in Metastatic Non-small Cell Lung Cancer in 100 participants. Completed in 23 May 2022.

Timeline

27 June 2019

Primary endpoint
30 July 2021

23 May 2022

Quick facts

Lead sponsor	Centre Hospitalier Departemental Vendee
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	100
Start date	27 June 2019
Primary completion	30 July 2021
Estimated completion	23 May 2022
Sites	2 locations across France

Drugs / interventions tested

ctDNA analysis — full drug profile →

Conditions studied

Metastatic Non-small Cell Lung Cancer — all drugs for Metastatic Non-small Cell Lung Cancer →

Sponsor

Centre Hospitalier Departemental Vendee

Who can join

18 and older, any sex, with Metastatic Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In patients with locally advanced or metastatic tumors, first-line therapeutic management is based on the use of targeted therapies (EGFR, BRAF ALK and ROS1 inhibitors), immunotherapies (anti-PD1/ anti-PDL1-antibodies or chemotherapy. Despite patient selection based on histo-pathological and molecular criteria, not all patients respond to treatment. There are currently no markers to definitively guarantee a patient's response. An alternative is to identify early patient response to treatment. The investigator hypothesize that change in circulating tumor DNA concentration (ctDNA) allow to early identify patients' therapeutic response (and non-response) of patients, regardless of the type of treatment used in the first line setting.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: Current research, opportunities, and challenges.
Sanz-Garcia E, Zhao E, Bratman SV, Siu LL. · · 2022 · cited 136× · PMID 35080978 · DOI 10.1126/sciadv.abi8618
Minimal Residual Disease, Metastasis and Immunity.
Badia-Ramentol J, Linares J, Gómez-Llonin A, Calon A. · · 2021 · cited 30× · PMID 33498251 · DOI 10.3390/biom11020130
Liquid biopsy into the clinics: Current evidence and future perspectives.
Boukovala M, Westphalen CB, Probst V. · · 2024 · cited 29× · PMID 40027149 · DOI 10.1016/j.jlb.2024.100146
Prognostic and Predictive Biomarkers in Non-Small Cell Lung Cancer Patients on Immunotherapy-The Role of Liquid Biopsy in Unraveling the Puzzle.
Augustus E, Zwaenepoel K, Siozopoulou V, Raskin J, et al · · 2021 · cited 21× · PMID 33918147 · DOI 10.3390/cancers13071675
An Immunological Perspective of Circulating Tumor Cells as Diagnostic Biomarkers and Therapeutic Targets.
Dotse E, Lim KH, Wang M, Wijanarko KJ, et al · · 2022 · cited 12× · PMID 35207611 · DOI 10.3390/life12020323
Absolute Quantification of Nucleotide Variants in Cell-Free DNA via Quantitative NGS: Clinical Application in Non-Small Cell Lung Cancer Patients.
Herbreteau G, Marcq M, Sauzay C, Carpentier M, et al · · 2025 · PMID 40075630 · DOI 10.3390/cancers17050783

Verify or expand the search:

Other trials of ctDNA analysis

Trials testing the same drug.

NCT05853198 — Circulating Tumor DNA as Surgical Biomarker in Patients With PancrEatic Adenocarcinoma for Statement of Resectability · NA · recruiting
NCT03808441 — CAcTUS - Circulating Tumour DNA Guided Switch · Phase 2 · unknown

Other recruiting trials for Metastatic Non-small Cell Lung Cancer

Currently open trials in the same condition.

NCT07024862 — Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With · active not recruiting
NCT06417814 — A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doub · Phase 3 · recruiting
NCT06428422 — The Impact of Probiotic on Survival and Treatment Response in Metastatic Non-small Cell Lung Cancer Patients · NA · recruiting
NCT05984277 — A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With · Phase 3 · active not recruiting
NCT06212752 — A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizu · Phase 3 · active not recruiting

Other Centre Hospitalier Departemental Vendee trials

Trials by the same sponsor.

NCT07489820 — Evaluation of the Efficacy of Negative Pressure Wound Therapy on Perineal Healing Following Abdominoperineal Amputation · NA · not yet recruiting
NCT07313293 — Impact of Foot Reflexology on Nausea After Obesity Surgery · NA · recruiting
NCT07314632 — Prospective Study in Laser Treatment of Pilonidal Cysts · recruiting
NCT07340060 — Statistical Association Between Bicarbonate Levels and Death or Admission to Intensive Care Within 48 Hours in Patients · recruiting
NCT07228767 — Assessment of Surgeons' Mental Fatigue Based on Operating Time · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03926260 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Departemental Vendee
Last refreshed: 4 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03926260.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing